Rehovot, Israel — September 4, 2025 — Leads & Copy — Purple Biotech Ltd. (NASDAQ/TASE: PPBT) has announced the pricing of a public offering totaling $6 million. The offering includes 5,999,999 American Depositary Shares (ADSs) or pre-funded warrants, each representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs, priced at $1.00 per share and accompanying warrants.
The short-term warrants, exercisable immediately upon issuance, have an exercise price of $1.00 per ADS and will expire 24 months from the issuance date. The offering is expected to close around September 5, 2025, pending customary conditions.
H.C. Wainwright & Co. is the exclusive placement agent. The company anticipates using the net proceeds to advance its oncology therapeutic candidates, as well as for general working capital and corporate purposes.
The SEC has declared the registration statement on Form F-1 effective. The offering is conducted via a prospectus, available on the SEC’s website and from H.C. Wainwright & Co., LLC. at (212) 856-5711 or placements@hcwco.com.
IR@purple-biotech.com
Source: Purple Biotech
